Rintega Receives Breakthrough Designation for EGFRvIII-Positive Glioblastoma
Rintega (rindopepimut) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the EGFR variant (EGFRvIII).